Zachary Zubulake

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus in Houston, part of a $40 billion five-year US investment pledge.

Cencora's Brent Wilhelm explains why final-mile drug delivery hinges on carrier network visibility, and how AI is helping route around weather-driven disruptions.

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap.

A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain and pricing risks.

Pharma companies could face 100% tariffs under new US rules, with relief available for those prioritizing onshore manufacturing or pricing concessions.

The FDA’s Plausible Mechanism Framework is designed to facilitate the approval of highly individualized therapies for patients with ultra-rare diseases.

The Supreme Court invalidated IEEPA-based tariffs, but pharmaceutical tariffs imposed under Section 232 remain in effect.